Unaudited (Standalone and Consolidated) Financial Results for 31.12.2025 along with Limited Review Report thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories reported consolidated revenue from operations of Rs. 4,036.64 lakhs for Q3 FY26, up about 7% from Rs. 3,770.70 lakhs in Q3 FY25. For the nine months ended December 31, 2025, consolidated revenue grew to Rs. 11,178.59 lakhs versus Rs. 9,757.77 lakhs last year, a rise of roughly 15%. Consolidated net profit for Q3 stood at Rs. 599.22 lakhs (vs Rs. 506.52 lakhs, up ~18% YoY) and for 9M at Rs. 1,652.02 lakhs (vs Rs. 1,509.50 lakhs, up ~9% YoY). Standalone Q3 revenue was Rs. 2,817.63 lakhs with net profit of Rs. 445.10 lakhs. The company recorded Rs. 30 lakhs as exceptional items in Q3 both on standalone and consolidated basis. Statutory auditor R Pugalia & Co. issued a limited review report with no material qualifications noted. The board also appointed Ms. Khushbu Kachhawa as an Independent Woman Director in place of Ms. Shilpa Bung and reconstituted key committees.
Steady but modest growth across revenue and profits with margins broadly stable; no negative audit flags or going concern issues. Likely a neutral-to-slightly-positive read for shareholders, with the board refresh being routine governance.